Ac Immune S.A.
18 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
10
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 25 to 27, 2026 · next Dec 25
- 1 fee due Jan 2, 2027The maintenance fee for Anti-Tau Antibodies and Methods of Use (US 10,336,819) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Polynucleotides encoding an anti-beta-amyloid monoclonal antibody (US 9,146,244) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due May 14, 2027The maintenance fee for Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates (US 11,814,378) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 2 fees due Jun 10 to 29, 2027 · next Jun 10
- 1 fee due Sep 22, 2027The maintenance fee for Vaccine Engineering (US 9,289,488) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 3 fees due Oct 16 to 28, 2027 · next Oct 16
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 2 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,603,487 | Palmitoylated AB 1-15 in a liposome as a treatment for amyloid associated diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,124,353 | Methods of Treating and Monitoring Disease with Antibodies In force · High confidence | In force | High confidence | |
| US 8,246,954 | Methods of Treating Amyloidosis with Humanized Anti-Beta-Amyloid Antibodies In force · High confidence | In force | High confidence | |
| US 7,892,544 | Humanized Anti-Beta-Amyloid Antibody In force · High confidence | In force | High confidence | |
| US 7,807,175 | Therapeutic vaccine In force · From the USPTO record | In force | From the USPTO record | |
| US 9,585,956 | Polynucleotides Encoding Anti-Amyloid Beta Monoclonal Antibodies In force · High confidence | In force | High confidence | |
| US 7,772,375 | Monoclonal antibodies that recognize epitopes of amyloid-beta In force · From the USPTO record | In force | From the USPTO record | |
| US 9,146,244 | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 12,653,872 | Mimotopes of Alpha-Synuclein and Vaccines Thereof for the Treatment of Synucleinopathy In force · Low confidence | In force | Low confidence | |
| US 9,403,902 | Methods of Treating Ocular Disease Associated with Amyloid-Beta-Related Pathology Using an Anti-Amyloid-Beta Antibody In force · High confidence | In force | High confidence |
Also on record, not counted in the 44: 18 patents in force now held by others · 8 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
19 pending · 16 abandoned · 28 no status recorded